NRX Pharmaceuticals Inc Market Cap ($58.91 Million)
Market Cap & Net Worth: NRX Pharmaceuticals Inc (NRXP)
NRX Pharmaceuticals Inc market cap. NRX Pharmaceuticals Inc (NASDAQ:NRXP) has a market capitalization of $58.91 Million ($58.91 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21064 globally and #4757 in its home market, demonstrating a -12.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NRX Pharmaceuticals Inc's stock price $2.24 by its total outstanding shares 29605150 (29.61 Million). Also see NRXP cash flow conversion for how efficiently the company converts equity into cash flow.
NRX Pharmaceuticals Inc Market Cap History (2017–2026)
NRX Pharmaceuticals Inc market cap history from 2017 to 2026. Data shows change from $2.87 Billion to $66.32 Million (-34.38% CAGR). Check NRX Pharmaceuticals Inc stock price for real-time trading data and today's change.
Index Memberships
NRX Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #597 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2005 of 3165 |
Weight: NRX Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NRX Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NRX Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NRX Pharmaceuticals Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NRXP by Market Capitalization
Companies near NRX Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see NRX Pharmaceuticals Inc (NRXP) total assets for a full breakdown of the balance sheet.
Key companies related to NRX Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of NRX Pharmaceuticals Inc (2017–2026)
Market capitalization of NRX Pharmaceuticals Inc from 2017 to today. Between 2017 and today, NRX Pharmaceuticals Inc's market cap moved from $2.87 Billion to $ 66.32 Million, with a yearly change of -34.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $66.32 Million | -17.34% |
| 2025 | $80.23 Million | +23.18% |
| 2024 | $65.13 Million | -52.17% |
| 2023 | $136.18 Million | -58.56% |
| 2022 | $328.62 Million | -76.78% |
| 2021 | $1.42 Billion | -80.41% |
| 2020 | $7.22 Billion | +130.19% |
| 2019 | $3.14 Billion | +3.92% |
| 2018 | $3.02 Billion | +5.37% |
| 2017 | $2.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of NRX Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.91 Million USD |
| MoneyControl | $58.91 Million USD |
| MarketWatch | $58.91 Million USD |
| marketcap.company | $58.91 Million USD |
| Reuters | $58.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more